3 ms·
There is an enormous amount of money in a cure, mitigation is mere tactical profit that you take when there is no obvious cure. The thing to remember is that, a
by jandrewrogers 11y ago
There is an enormous amount of money in a cure, mitigation is mere tactical profit that you take when there is no obvious cure. The thing to remember is that, at least in the US biotech market, there are a large number of companies competing for those profits. Patients benefit immensely from mitigation research -- look at HIV. A lot of mitigation therapies were originally "cures" that did not work as well as hoped.
At any point in time, patients have the choice across the spectrum of mitigations or cures. Cures are more difficult to produce but if they are available patients will choose them every time. Companies that produce mitigating medicine are counting on their ability to recoup investment before a cure materializes at some point in the future. If a cure becomes available, the value of their mitigation research goes to zero. Biomedical companies make bets that, if a disease looks particularly difficult to cure, mitigation will retain its value long enough to return a profit as a product.
Most biomedical research companies are looking for cures because it allows them to do an end run around their competitors and grab most of the profits. Every biomedical company wants a cure because it completely displaces competitive mitigation strategies and therefore allows them to collect virtually all of the profits. Mitigation is the fallback position when cures fail. But biomedical research is looking for the cure that will give the a naturally monopoly position by default.